The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials

@article{AlsheikhAli2009TheRO,
  title={The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials},
  author={Alawi Alsheikh-Ali and Richard H Karas},
  journal={Current Atherosclerosis Reports},
  year={2009},
  volume={11},
  pages={100-104}
}
  • Alawi Alsheikh-Ali, Richard H Karas
  • Published 2009
  • Medicine
  • Current Atherosclerosis Reports
  • Abstract3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are among the most commonly prescribed and studied drugs in modern medicine. Their proven benefit in prevention of cardiovascular events is driven by their ability to markedly reduce low-density lipoprotein cholesterol (LDL-C). Recent analyses have provided insight into the relationship between statin-induced reductions in LDL-C and risk of rhabdomyolysis, liver toxicity, and cancer. Risk of statin-associated elevated… CONTINUE READING

    Topics from this paper.

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The primary objective is to evaluate the efficacy of FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome; The secondary… Expand
    ConditionsMetabolic Syndrome
    InterventionDietary Supplement

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 17 CITATIONS

    Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies.

    VIEW 1 EXCERPT
    CITES BACKGROUND
    HIGHLY INFLUENCED